​Fertility and maternal health are entering a new phase of AI-driven innovation.

​Fertility and maternal health are entering a new phase of AI-driven innovation.

​From personalised nutritional guidance and diagnostic modelling to remote care delivery, AI is beginning to reshape how reproductive healthcare is delivered and experienced.

​The opportunity is significant.
Regulatory, architectural, and ethical considerations shape how these technologies are designed, validated, and deployed.

​On 31 March, MOHARA is hosting a roundtable on AI in fertility tech, bringing together founders, product leaders, clinicians, and early-stage investors to explore what it takes to build AI-powered fertility platforms that are safe, scalable, and investment-ready.

​The conversation will feature perspectives from across the ecosystem:

​Dawn Chan — Founder of SOW Fertility, a Hong Kong-based platform focused on improving access to fertility care and guidance across Asia.

​Alik Christianian — AI and product leader working at the intersection of machine learning, healthcare infrastructure, and applied AI systems.

​Chris Brereton — Operating Partner at MOHARA, focused on healthcare innovation and helping early and growth-stage companies translate strategy into scalable products and operations.

Moderated by MOHARA Co-CEO and Co-Founder Richard Sams.

​Together, the panel will explore how emerging technologies are shaping fertility care, what responsible AI deployment looks like in clinical contexts, and where meaningful value is emerging across the reproductive health ecosystem.

​What We’ll Explore

​• Where AI is creating genuine defensible value in fertility and maternal health
• Precision-driven care and the technologies improving clinical outcomes
• Designing AI-enabled platforms for telehealth and remote care environments
• Regulatory strategy and its role in shaping product design
• Signals investors look for in AI-enabled healthcare platforms
• Building resilient products in clinically sensitive environments

​Who This Is For

​• Fertility and maternal health founders (Pre-Seed to Series B)
• Product and technical leaders building AI-enabled healthcare platforms
• Early-stage investors focused on women’s health, digital health, and precision medicine
• Operators navigating AI in regulated clinical environments

​Attendance is reviewed to ensure a high-signal conversation.

​Format

​• 45-minute moderated discussion
• 15-minute audience Q&A
• Curated post-event insight summary shared with all registrants